METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to control advanced prostate cancer
Disease control Not yet recruitingThis early-stage trial tests the safety of combining a radioactive drug (lutetium-177 DGUL) with an immunotherapy (pembrolizumab) in men with metastatic castration-resistant prostate cancer that has stopped responding to standard hormone therapy. About 30 participants will receiv…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 07:58 UTC
-
Could a common Alzheimer's drug fight prostate cancer?
Disease control Not yet recruitingThis study tests whether memantine hydrochloride, a drug typically used for Alzheimer's, can help control advanced prostate cancer that has stopped responding to standard treatments. Fifteen men with metastatic castration-resistant prostate cancer will take the drug alongside the…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Bin Xu • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New drug combo aims to control advanced breast cancer
Disease control Not yet recruitingThis study tests a new drug called ERW316, alone or with hormone therapy, in people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and check for side effects. About 217 adults will take part ac…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with a specific type of advanced prostate cancer that has stopped responding to standard treatments. It uses a special imaging agent to find cancer cells and then delivers targeted radiation to destroy them. The goal is to see if this combi…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
CBD trial aims to cut opioid use in End-Stage prostate cancer patients
Symptom relief Not yet recruitingThis study tests whether cannabidiol (CBD) can reduce the need for strong painkillers (opioids) in people with end-stage prostate cancer that no longer responds to standard treatments. About 58 participants will receive either CBD or a placebo three times daily for nine weeks. Re…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE2 • Sponsor: Regionshospital Nordjylland • Aim: Symptom relief
Last updated May 26, 2026 07:52 UTC